In Vitro Activities of Garenoxacin (BMS-284756) against 170 Clinical Isolates of NinePasteurellaSpecies

Abstract

ABSTRACTThe in vitro susceptibilities of 170 clinical isolates plus 12 American Type Culture Collection strains ofPasteurellaspecies comprising nine species and threePasteurella multocidasubspecies were studied by an agar dilution method. Garenoxacin (BMS-284756), a new des-fluoro(6) quinolone, was active at ≤0.06 μg/ml against all isolates, including four β-lactamase-producing strains, with >90% of the strains susceptible to ≤0.008 μg/ml. Garenoxacin was generally 1 to 2 dilutions more active than levofloxacin and moxifloxacin and was the most active agent tested. Cefoxitin required 1 μg/ml for inhibition of 51 of 182 (29%) of strains, and 3 strains (also β-lactamase producers) were resistant to doxycycline.